The subscription period in STENOCARE A/S’s new share issue begins today

Today, September 24th, 2018, the subscription period in STENOCARE A/S’s ("STENOCARE" or the “Company”) new share issue prior to planned listing on Spotlight Stock Market ("Spotlight") begins. The subscription period ends on October 9th, 2018. With a fully subscribed new share issue, the Company will receive approximately DKK 18.6 million before issue costs. The Company has in advance signed subscription commitments of DKK 11.2 million, corresponding to approximately 60 percent of the total issue volume. Memorandum, teaser and subscription forms are available through the websites of STENOCARE (www.stenocare.com/Investor), Sedermera Fondkommission (www.sedermera.se) and Gemstone Capital (www.gemstonecapital.com). The investment documents are also available via Spotlight’s website (www.spotlightstockmarket.com). Subscription of shares can be made by submitting a subscription form to Sedermera Fondkommission or through their website (via BankID) or Nordnet Bank (www.nordnet.se). For subscription of shares directly through other banks, the subscriber is asked to contact his or her bank.

About STENOCARE and the new share issue

On January 1st, 2018, the Danish parliament initiated a four-year trial-programme (“the Programme”) allowing all physicians in Denmark to prescribe medical cannabis. The purpose of the Programme is to provide patients in need with a legal opportunity to receive treatment with medical cannabis.

STENOCARE was the first company in the Danish market to receive licenses from the Danish Medicines Agency to both cultivate, produce as well as import medical cannabis. As a result, STENOCARE is the first and presently only vendor under this Programme that has commenced delivering medical cannabis oil products to the Danish pharmacies and hospitals through the two leading wholesalers of medicine in Denmark.

The initial products are imported from STENOCAREs Canadian partner, CannTrust [TSX: TRST] and are available at scale. The products are high quality pharmaceutical grade medical cannabis oils, produced through hygienic cultivation and processing without the use of pesticides. STENOCARE currently offers three products: CBD Drops STENOCARE, THC Drops STENOCARE and 1:1 Drops STENOCARE.

In addition, STENOCARE will develop a separate production facility for the cultivation and production of its own medical cannabis products at the Company’s premises in Jutland, Denmark. In order to finance this as well as operational cost, the Company is now raising capital equivalent to approximately DKK 18.6 million before issue costs, prior to the planned listing on Spotlight.

CEO and co-founder Thomas Skovlund Schnegelsberg

“STENOCARE has created a leadership role in Denmark through our ability to secure approvals from the Danish Medicines Agency, and compared to our 30+ competitors, we have completed many vital milestones in our path towards helping patients having a better quality of life. We warmly welcome new investors to invest in STENOCARE and joining our journey to provide better quality of life for patients and succeeding in a new industry with high growth potential in Denmark and Europe”. 

New share issue – the offer in brief

Subscription period: 24 September – 9 October 2018.
Subscription price: DKK 8.80 per share.
Subscription post: Minimal subscription post is 400 shares.
New share issue volume and minimal limit: The offer comprises no more than 2,113,000 shares, equivalent to DKK 18,594,400. The minimum limit for the new share issue’s implementation is DKK 11,088,000.
Number of shares before the new share issue: 6,784,762 shares.
Valuation (pre-money): Approx. DKK 59.7 million.
Subscription commitments: The Company has received subscription commitments of approximately DKK 11.2 million, a total of approx. 60 percent of the issue volume. This includes subscription commitments from the Board of Directors, the management and the main shareholders.
Listing on Spotlight: STENOCARE has been approved for listing on Spotlight, provided that the ownership spread requirements are met. The Company’s shares are planned for listing on the 26th of October, 2018, under the short name “STENO”.
ISIN code: DK0061078425.

Investor meetings

In connection with the new share issue, representatives from STENOCARE will present the business, the team and future plans at the following investor meetings:

Financial Advisor

Sedermera Fondkommission is the financial advisor to STENOCARE in connection with the new share issue and the listing on Spotlight. Nordnet Bank AB is acting as Selling Agent in the new share issue. Gemstone Capital is assisting the Company regarding marketing in Denmark, etc.

More information

For further introduction to the Company and the offer, please refer to the Company’s memorandum (in English and Swedish), teaser (in Danish and Swedish), and subscriptions forms which are available through the websites of STENOCARE (www.stenocare.com/Investor), Sedermera Fondkommission (www.sedermera.se) and Gemstone Capital (www.gemstonecapital.com). The investment documents are also available at Spotlight’s website (www.spotlightstockmarket.com).

For additional information regarding the new share issue and planned listing, please contact:

Sedermera Fondkommission

Phone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

through Press-coordinator Lisbeth Grænge Hansen
Phone: +45 30 16 10 97

E-mail: presse@stenocare.com

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis trial-programme. STENOCARE was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE offers high quality pharmaceutical grade medical cannabis oils, which are produced by hygienic and high technology cultivation and processing without the use of pesticides. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.